Thursday, October 01, 2015 9:34:21 PM
Why buy TTPH right now? >>>
Because it's a marginable security with HUGE upside and minimal downside, now that a bottom has finally been established. MACD strongly confirms it:
TTPH is currently and extremely an oversold hidden gem due to disappointing biotech news at the same time as China's negative growth combined with Hillary Clinton's comments on high drug prices. Between those two events, many biotechs just suffered their worst week in years.
“We previously announced (12/17/14) positive data from the IGNITE1 phase 3 clinical trial of eravacycline administered intravenously in complicated intra-abdominal infections which did meet its primary endpoint, demonstrating high cure rates in prevalent Gram-negative pathogens and a favorable safety profile.”
However, as bad as the failure of the IGNITE 2 trials may have been, the IGNITE 1 phase trials/results still stand solid.
IGNITE 1 results, which are still totally solid, suggest TTPH should still range $20-$30, as above chart shows.
Sheff, I wouldn't waste you or your board's time, if I didn't seriously believe in an oversold condition that could be a profit to all respected people her.
Because it's a marginable security with HUGE upside and minimal downside, now that a bottom has finally been established. MACD strongly confirms it:
TTPH is currently and extremely an oversold hidden gem due to disappointing biotech news at the same time as China's negative growth combined with Hillary Clinton's comments on high drug prices. Between those two events, many biotechs just suffered their worst week in years.
“We previously announced (12/17/14) positive data from the IGNITE1 phase 3 clinical trial of eravacycline administered intravenously in complicated intra-abdominal infections which did meet its primary endpoint, demonstrating high cure rates in prevalent Gram-negative pathogens and a favorable safety profile.”
However, as bad as the failure of the IGNITE 2 trials may have been, the IGNITE 1 phase trials/results still stand solid.
IGNITE 1 results, which are still totally solid, suggest TTPH should still range $20-$30, as above chart shows.
Sheff, I wouldn't waste you or your board's time, if I didn't seriously believe in an oversold condition that could be a profit to all respected people her.
Please don't ask me for a member mark. I earned mine and I expect others to, also.
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
